Recent Updates
Recently added Catalysts
ONC Positive Sentiment

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Saturday, October 24, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: BeOne Medicines Ltd. presented new data on its investigational medicines at the ESMO Congress 2026. The findings focus on hard-to-treat liver and lung cancers, showcasing the company's advancements in solid tumor therapies. This presentation highlights the increasing momentum of BeOne's solid tumor franchise.

Market Sentiment Analysis

POSITIVE FACTORS

  • New data presented at ESMO 2026
  • Focus on hard-to-treat liver and lung cancers
  • Growing momentum in solid tumor franchise

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+47%
120-day peak, hindsight
Typical move
3.2%
average across 8 past catalysts
Lead asset
BGB-43395
Phase 1 · Advanced Solid Tumor

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.

Frequently Asked Questions

What data did BeOne present at ESMO 2026?

BeOne presented data on investigational medicines for liver and lung cancers.

Where was the ESMO Congress 2026 held?

The ESMO Congress 2026 took place in Madrid from October 23 to 27.

What types of cancers are focused on by BeOne?

BeOne focuses on gastrointestinal, lung, and breast cancers.

Who is Mark Lanasa?

Mark Lanasa, M.D., is associated with BeOne Medicines.

ShareAdd on Google
Tags: ONC BeOne Medicines ESMO 2026 solid tumors liver cancer lung cancer
Last updated: Oct 24, 2026

Biotech snapshot

Cash runway
$5098M liquidity · $0M/mo burn
Low dilution risk
Lead asset
BGB-43395Phase 1
Advanced Solid Tumor →

Catalyst track record

+47%
best trade around ONC's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for ONC.

See every catalyst's timing & PoA →